Prescient Medical to showcase its vProtect Luminal Shield and the vPredict Optical Catheter System

Two products from Prescient Medical -- the vProtect(TM) Luminal Shield and the vPredict(TM) Optical Catheter System -- will be featured at the 3rd Annual Canaccord Adams Cardiovascular Conference. The conference will take place on Tuesday, November 10th in San Francisco, California, and will bring together a select group of med-tech and biotech companies focused on the most important markets in cardiovascular medicine. Prescient Medical is one of only fifteen development-stage private companies invited to present to potential investors at the conference.

The vProtect(TM) Luminal Shield is a novel self-expanding coronary stent system that received CE Mark certification in August, 2009 for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease. The Shield also was recently honored with Frost & Sullivan's 2009 North American Product Innovation of the Year Award. Designed specifically to minimize arterial injury and its consequences, the Shield is ideal for treating softer plaques, including plaques in patients who have recently suffered a heart attack and so-called "vulnerable" plaques.

Vulnerable plaques are prone to rupture, causing a release of cholesterol and cellular debris into the blood stream that often results in a clot that obstructs blood flow to the heart, thus causing a heart attack.

The vPredict(TM) Optical Catheter System is being developed for the detection and characterization of vulnerable plaque. The vPredict(TM) Optical Catheter System platform is based on Raman spectroscopy, a highly sensitive technology that is used in scores of critical non-clinical applications. The vPredict(TM) Optical Catheter System detects the clinically important compounds, including cholesterols, in the vessel wall and plaque.

"We are pleased to have our products featured at the Canaccord Adams Cardiovascular Conference," said Prescient CEO Patricia Scheller. "We believe our products have the potential to revolutionize the practice of interventional cardiology by enabling physicians to better treat and ultimately to prevent heart attacks."